Skip to main content

Daniel A. Ermann, MD Awarded Merit Award from the American Society of Clinical Oncology (ASCO)

May 16, 2022

Daniel A. Ermann, MD Awarded Merit Award from the American Society of Clinical Oncology (ASCO)

Who I am: (Daniel A. Ermann, MD)

My name is Daniel Ermann, second-year hematology/oncology fellow at Huntsman Cancer Institute. I earned my M.D. from Medical School at St. George’s University and went onto Internal Medicine Residency at Creighton University in Omaha, Nebraska. Following this I pursued my fellowship training in Hematology/Oncology at Huntsman (HCI) and am planning to specialize in the treatment and management of Lymphoma malignancies, with an interest in Non-Hodgkin Lymphoma. Additionally, I have been training to be a Clinical Researcher working on ground-breaking Clinical Trials for Lymphoma patients under the expert mentorship of Dr. Deborah Stephens and Dr. Boyu Hu.

What is the award: Conquer Cancer, ASCO Foundation, Merit Award from the American Society of Clinical Oncology (ASCO)

This is a limited award, given to few select applicants, that is designated only to Oncology Fellows whose research is high-quality and has excellent scientific merit

These award recipients are honored with the opportunity to present their first-author research at the Annual Scientific Meeting (ASCO), receive $1,000 in monetary support, complimentary registration, and access to additional benefits.

How I did the research: Database Study, National Cancer Database (NCDB)

For this study, we utilized the National Cancer Database. This a large and powerful oncology registry that captures up to 70% of newly diagnosed malignancies in the United States annually. This database provides opportunities for clinical study research and high quality outcomes analysis, and includes patients with Non-Hodgkin Lymphoma.

Study Title: Racial Disparities Affecting Black Patients with Diffuse Large B-cell Lymphoma.

Key Findings:

  1. Compared to age-matched White patients, younger Black patients (age < 80) and had worse median survival and worse overall survival at both 5- and 10-years.

  2. Black race was independently associated with worse OS (HR 1.06, CI 1.01-1.10, p=0.02) when compared to White race.

  3. Propensity matched analysis for surrogate markers of health care access showed non-significant difference in survival, suggesting further studies evaluating these racial disparities is warranted.